Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-ranging Study to Assess the Efficacy and Safety of CDX-0159 in Patients With Chronic Inducible Urticaria

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Barzolvolimab (Primary)
Indications Chronic urticaria; Cold Urticaria; Familial dermographism
Focus Therapeutic Use
Sponsors Celldex Therapeutics Inc

Most Recent Events

01 Mar 2025 According to a Celldex Therapeutics Inc Media Release, data were presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2025.
01 Mar 2025 Results presented in the Celldex Therapeutics Inc Media Release.
26 Oct 2024 According to a Celldex Therapeutics Inc Media Release, company will host a webcast call Monday at 8:00 am ET.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com